SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14396)2/6/1998 9:26:00 PM
From: RXGOLF  Read Replies (2) | Respond to of 32384
 
Henry,
Recently we were discussing the needs of the big boys to replenish their money makers going off patent.In all of 1997, the FDA cleared 431 brand-name copies including Zantac and Coumadin. This was 80 more than the previous year. Maybe Ligand can help fill some of these voids. 39 of the approvals were "first time" generics.
RXGOLF


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News